{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:28:19Z","timestamp":1784903299942,"version":"3.55.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.path.2024.10.001","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T07:34:45Z","timestamp":1733211285000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Molecular Landscape of Aggressive Histologic Subtypes of Localized Prostate Cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Chien-Kuang C.","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Y.","family":"Greenland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepika","family":"Sirohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5748","key":"10.1016\/j.path.2024.10.001_bib1","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.21037\/tau.2017.12.33","article-title":"On cribriform prostate cancer","volume":"7","author":"Kweldam","year":"2018","journal-title":"Transl Androl Urol"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.path.2022.07.001","article-title":"Cribriform lesions of the prostate gland","volume":"15","author":"Cai","year":"2022","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib4","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/his.15102","article-title":"Large cribriform glands (> 0.25 mm diameter) as a predictor of adverse pathology in men with Grade Group 2 prostate cancer","volume":"84","author":"Greenland","year":"2024","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.path.2024.10.001_bib5","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41379-019-0221-0","article-title":"Three-dimensional analysis reveals two major architectural subgroups of prostate cancer growth patterns","volume":"32","author":"Verhoef","year":"2019","journal-title":"Mod Pathol"},{"issue":"30","key":"10.1016\/j.path.2024.10.001_bib6","doi-asserted-by":"crossref","first-page":"11139","DOI":"10.1073\/pnas.1411446111","article-title":"Copy number alteration burden predicts prostate cancer relapse","volume":"111","author":"Hieronymus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.eururo.2017.04.034","article-title":"A\u00a0prostate cancer \"nimbosus\": genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies","volume":"72","author":"Chua","year":"2017","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.path.2024.10.001_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/1541-7786.MCR-18-0440","article-title":"Genetic and epigenetic determinants of aggressiveness in cribriform carcinoma of the prostate","volume":"17","author":"Elfandy","year":"2019","journal-title":"Mol Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/his.13273","article-title":"Atypical intraductal proliferation and intraductal carcinoma of the prostate on core needle biopsy: a comparative clinicopathological and molecular study with a proposal to expand the morphological spectrum of intraductal carcinoma","volume":"71","author":"Shah","year":"2017","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib10","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/modpathol.2012.201","article-title":"Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia","volume":"26","author":"Lotan","year":"2013","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.path.2024.10.001_bib11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/pcan.2013.8","article-title":"Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion","volume":"16","author":"Gumuskaya","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/path.2154","article-title":"Morphological features of TMPRSS2-ERG gene fusion prostate cancer","volume":"212","author":"Mosquera","year":"2007","journal-title":"J\u00a0Pathol"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12885-017-3976-z","article-title":"Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations","volume":"18","author":"Bottcher","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.path.2024.10.001_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.humpath.2017.04.024","article-title":"PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform","volume":"65","author":"Ronen","year":"2017","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.path.2024.10.001_bib16","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/pros.23831","article-title":"PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma)","volume":"79","author":"Shah","year":"2019","journal-title":"Prostate"},{"issue":"8","key":"10.1016\/j.path.2024.10.001_bib17","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jmoldx.2021.05.006","article-title":"Assessment of MYC\/PTEN status by gene-protein assay in grade group 2 prostate biopsies","volume":"23","author":"Salles","year":"2021","journal-title":"J\u00a0Mol Diagn"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib18","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/his.14531","article-title":"PTEN expression and morphological patterns in prostatic adenocarcinoma","volume":"79","author":"Spieker","year":"2021","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.path.2024.10.001_bib19","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/his.14645","article-title":"Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer","volume":"80","author":"Wyvekens","year":"2022","journal-title":"Histopathology"},{"issue":"22","key":"10.1016\/j.path.2024.10.001_bib20","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-17-0955","article-title":"MSH2 loss in primary prostate cancer","volume":"23","author":"Guedes","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3892\/ol.2017.6140","article-title":"Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors","volume":"14","author":"Olkhov-Mitsel","year":"2017","journal-title":"Oncol Lett"},{"issue":"13","key":"10.1016\/j.path.2024.10.001_bib22","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S1470-2045(14)71113-1","article-title":"RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1","volume":"15","author":"Prensner","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib23","doi-asserted-by":"crossref","first-page":"6036","DOI":"10.1038\/s41467-022-33780-1","article-title":"Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib24","first-page":"90","article-title":"Correlation of a commercial genomic risk classifier with histological patterns in prostate cancer","volume":"202","author":"Greenland","year":"2019","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.path.2024.10.001_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/pros.23926","article-title":"Correlation between cribriform\/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier","volume":"80","author":"Taylor","year":"2020","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.euf.2022.05.005","article-title":"Transcriptomic features of cribriform and intraductal carcinoma of the prostate","volume":"8","author":"Lone","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4111\/icu.20210262","article-title":"Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer","volume":"63","author":"Greenland","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.path.2024.10.001_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.06.007","article-title":"Proliferation index of different Gleason pattern 4 histomorphologies and associated pattern 3 adenocarcinoma of the prostate","volume":"70","author":"Fu","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.path.2024.10.001_bib29","doi-asserted-by":"crossref","first-page":"104400","DOI":"10.1016\/j.yexmp.2020.104400","article-title":"Comparative expression of immunohistochemical biomarkers in cribriform and pattern 4 non-cribriform prostatic adenocarcinoma","volume":"114","author":"Xiao","year":"2020","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib30","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cjp2.205","article-title":"A\u00a0distinct repertoire of cancer-associated fibroblasts is enriched in cribriform prostate cancer","volume":"7","author":"Hesterberg","year":"2021","journal-title":"J\u00a0Pathol Clin Res"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/PAP.0000000000000303","article-title":"Intraductal carcinoma of the prostate: a guide for the practicing pathologist","volume":"28","author":"Varma","year":"2021","journal-title":"Adv Anat Pathol"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib32","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/1097-0045(20000901)44:4<265::AID-PROS1>3.0.CO;2-I","article-title":"Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression","volume":"44","author":"Dawkins","year":"2000","journal-title":"Prostate"},{"issue":"7","key":"10.1016\/j.path.2024.10.001_bib33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/gcc.20560","article-title":"Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate","volume":"47","author":"Bettendorf","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib34","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/PAS.0b013e3181d6827b","article-title":"ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia","volume":"34","author":"Han","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib35","first-page":"31","article-title":"Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization","volume":"238","author":"Nelson","year":"2016","journal-title":"Cancer Prev Res"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/path.4628","article-title":"Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization","volume":"238","author":"Haffner","year":"2016","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.path.2024.10.001_bib37","doi-asserted-by":"crossref","first-page":"13671","DOI":"10.1038\/ncomms13671","article-title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","volume":"8","author":"Taylor","year":"2017","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2014.08.007","article-title":"Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis","volume":"67","author":"Risbridger","year":"2015","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Isaacsson Velho","year":"2018","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.path.2024.10.001_bib40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/path.5283","article-title":"Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations","volume":"249","author":"Khani","year":"2019","journal-title":"J\u00a0Pathol"},{"issue":"1\u20132","key":"10.1016\/j.path.2024.10.001_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","article-title":"PARP inhibitors for prostate cancer","volume":"51","author":"Longoria","year":"2024","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","article-title":"Prostate cancer, version 3.2024","volume":"22","author":"Schaeffer","year":"2024","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.path.2024.10.001_bib43","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2021.01.027","article-title":"Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer","volume":"147","author":"Lozano","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.path.2024.10.001_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.humpath.2024.01.005","article-title":"Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway","volume":"144","author":"Mahlow","year":"2024","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00428-013-1385-5","article-title":"Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens","volume":"462","author":"Seipel","year":"2013","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.path.2024.10.001_bib46","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/his.12382","article-title":"Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists","volume":"65","author":"Seipel","year":"2014","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib47","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.pathol.2016.04.001","article-title":"Ductal adenocarcinoma of the prostate: histogenesis, biology and clinicopathological features","volume":"48","author":"Seipel","year":"2016","journal-title":"Pathology"},{"issue":"2","key":"10.1016\/j.path.2024.10.001_bib48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.eururo.2020.11.015","article-title":"Ductal prostate cancers demonstrate poor outcomes with conventional therapies","volume":"79","author":"Ranasinghe","year":"2021","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.path.2024.10.001_bib49","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/modpathol.2009.79","article-title":"Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma","volume":"22","author":"Han","year":"2009","journal-title":"Mod Pathol"},{"issue":"14","key":"10.1016\/j.path.2024.10.001_bib50","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/pros.23042","article-title":"PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas","volume":"75","author":"Morais","year":"2015","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib51","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00428-014-1636-0","article-title":"Immunohistochemical profile of ductal adenocarcinoma of the prostate","volume":"465","author":"Seipel","year":"2014","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib52","first-page":"381","article-title":"Clinical significance and EZH2, ERG and SPINK1 protein expression in pure and mixed ductal adenocarcinoma of the prostate","volume":"34","author":"Patil","year":"2019","journal-title":"Histol Histopathol"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib53","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/pros.24304","article-title":"Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin","volume":"82","author":"Lindh","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.path.2024.10.001_bib54","article-title":"Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations","volume":"3","author":"Schweizer","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib55","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.euf.2017.12.003","article-title":"Integrative genomic analysis of coincident cancer foci implicates CTNNB1 and PTEN alterations in ductal prostate cancer","volume":"5","author":"Gillard","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.path.2024.10.001_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.04.015","article-title":"Genetic profile of ductal adenocarcinoma of the prostate","volume":"69","author":"Seipel","year":"2017","journal-title":"Hum Pathol"},{"issue":"10","key":"10.1016\/j.path.2024.10.001_bib57","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1464-410X.2008.08074.x","article-title":"Rare and unusual histological variants of prostatic carcinoma: clinical significance","volume":"102","author":"Mazzucchelli","year":"2008","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.path.2024.10.001_bib58","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/00000478-200405000-00014","article-title":"Prostate carcinoma with squamous differentiation: an analysis of 33 cases","volume":"28","author":"Parwani","year":"2004","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.path.2024.10.001_bib59","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1097\/PAS.0000000000001112","article-title":"Prostatic adenocarcinoma with focal pleomorphic giant cell features: a series of 30 cases","volume":"42","author":"Alharbi","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib60","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/his.14205","article-title":"Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases","volume":"77","author":"Alhamar","year":"2020","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib61","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/his.12493","article-title":"Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin","volume":"66","author":"Rodrigues","year":"2015","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib62","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/j.clgc.2019.11.020","article-title":"Squamous transformation of prostate adenocarcinoma: a report of two cases with genomic profiling","volume":"18","author":"Dizman","year":"2020","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib63","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/modpathol.2011.7","article-title":"ERG gene rearrangements are common in prostatic small cell carcinomas","volume":"24","author":"Lotan","year":"2011","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib64","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/1724600818791463","article-title":"Carcinosarcoma of the prostate: case report with molecular and histological characterization","volume":"33","author":"Salvi","year":"2018","journal-title":"Int J Biol Markers"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib65","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/his.13806","article-title":"DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features","volume":"74","author":"Lotan","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.path.2024.10.001_bib66","doi-asserted-by":"crossref","first-page":"151719","DOI":"10.1016\/j.anndiagpath.2021.151719","article-title":"Pleomorphic giant cell carcinoma of prostate: rare tumor with unique clinicopathological, immunohistochemical, and molecular features","volume":"52","author":"El-Zaatari","year":"2021","journal-title":"Ann Diagn Pathol"},{"issue":"3","key":"10.1016\/j.path.2024.10.001_bib67","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00428-022-03481-7","article-title":"Pleomorphic giant cell carcinoma of the prostate: clinicopathologic analysis and oncological outcomes","volume":"482","author":"Bile-Silva","year":"2023","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib68","article-title":"Genomic characterization and molecular taxonomy of sarcomatoid variant prostate cancer","volume":"39","author":"Duong","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.path.2024.10.001_bib69","first-page":"689","article-title":"Immunohistochemical and Next-Generation sequencing (NGS) characterization of 19 cases of adenosquamous prostate carcinoma (PCa) of the prostate","volume":"102","author":"Villarroel","year":"2022","journal-title":"Lab Invest"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib70","article-title":"Comprehensive genomic sequencing of prostate sarcomatoid carcinoma tumors identifies differences in genomic alterations compared to prostate adenocarcinoma tumors","volume":"35","author":"Millis","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2024.10.001_bib71","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.path.2024.10.001_bib72","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.humpath.2022.07.002","article-title":"De novo neuroendocrine features in prostate cancer","volume":"127","author":"Abdulfatah","year":"2022","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.path.2024.10.001_bib73","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"6320","key":"10.1016\/j.path.2024.10.001_bib74","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"issue":"6320","key":"10.1016\/j.path.2024.10.001_bib75","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918124000783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:30:20Z","timestamp":1760074220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918124000783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1875918124000783"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2024.10.001","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Landscape of Aggressive Histologic Subtypes of Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2024.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}